4-(4-bromo-3-(hydroxyMethyl)phenoxy)benzonitrile

We are 4-(4-bromo-3-(hydroxyMethyl)phenoxy)benzonitrile CAS:906673-45-8 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:4-(4-bromo-3-(hydroxyMethyl)phenoxy)benzonitrile
CAS.NO:906673-45-8
Synonyms:2-bromo-5-(4-cyanophenoxy)benzyl alcohol
Molecular Formula:C14H10BrNO2
Molecular Weight:304.13900
 
 
Specification:
Appearance:Off-white to white powder
Purity:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Crisaborole (AN2728)
 
Note:The product under valid patents will not be offered to the countries covered by patents.

4-(4-bromo-3-(hydroxyMethyl)phenoxy)benzonitrile


Related News: Because API companies usually adopt a different synthetic route from the original research company, compared with the drug itself, the impurities contained in the generic drug API have not been verified by the original drug for many years of use and require more careful testing and control.5,6,7,8-Tetrahydroquinoxaline CAS:34413-35-9 Trial results demonstrated that Oligomannate statistically improved cognitive function in mild-to-moderate AD patients as early as week 4 and the benefit was sustained at each follow-up assessment visit,” Shanghai Green Valley Pharmaceuticals, which developed the drug along with two academic institutions in China, said in a statement.1-bromo-5-yodopentano CAS:88962-86-1 Trial results demonstrated that Oligomannate statistically improved cognitive function in mild-to-moderate AD patients as early as week 4 and the benefit was sustained at each follow-up assessment visit,” Shanghai Green Valley Pharmaceuticals, which developed the drug along with two academic institutions in China, said in a statement.Ácido 2-amino-4-fluorobenzoico CAS:446-32-2 API (Active Pharmaceutical Ingredient) means the active ingredient which is contained in medicine.The clinical trial International Study of Phase 3 IV RigosErtib, or INSPIRE, was finalized following guidance received from the U.S. Food and Drug Administration and European Medicines Agency.

Related Products
Product Name
(5-Bromo-2-chlorophenyl)(4-ethoxyphenyl)methanone View Details
[dimethylamino-(1-oxidopyridin-1-ium-2-yl)sulfanylmethylidene]-dimethylazanium,tetrafluoroborate View Details
Triethoxysilane View Details
5-amino-2-chlorobenzotrifluoride manufacturer Tosyl Isocyanate manufacturer 2-(2-Aminothiazol-4-yl)acetic acid hydrochloride manufacturer N-Boc-glycine methyl ester manufacturer 1H-1,2,3-Triazole manufacturer